Famous Patents
British merchant Peter Durand invented the tin can in 1810.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| RE40525 | Hepatitis C inhibitor tri-peptides A racemate diastereoisomer and optical isomer of a compound of formula (I): wherein B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which may be optionally substituted wi... | 09/30/2008 |
| 7378436 | Compounds A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein R1 is H, C1-6alkyl, —C(X)Y, C3-8cycloalkyl, aryl, het, aryl-C1-4alkyl ... | 05/27/2008 |
| 7304159 | Ligands and catalyst systems thereof for ethylene oligomerisation to linear alpha olefins Mixed bis-imine pyridine ligands of formula (I), wherein Z1, which is different from Z2, is an optionally substituted aryl group; and Z2 comprises an optionally substituted heterohydrocarbyl moiety, or an optionally substituted aryl ... | 12/04/2007 |
| 7253204 | Inhibitors of histone deacetylase The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and cond... | 08/07/2007 |
| 7238764 | Process for the co-oligomerisation of ethylene and alpha olefins A process for production of higher linear alpha olefins and/or alkyl-branched alpha olefins, which comprises the co-oligomerisation of one or more alpha olefins with ethylene in the presence of a metal catalyst system employing one or more bis-aryliminepyridine MX | 07/03/2007 |
| 7208600 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A ... | 04/24/2007 |
| 7173024 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use Compounds of the formula (I), wherein the symbol aa means a residue of an α-amino acid. The invention is also directed to a method for the preparation of the compounds of formula (I), as well as their use as pro... | 02/06/2007 |
| 7160902 | Amide derivatives and methods of their use Amide derivatives of the general formulae Ia and Ib: are disclosed. Pharmaceutical compositions containing these compounds, and methods for their use, inter alia, for treating and/or preventing gastrointestinal d... | 01/09/2007 |
| 7160834 | Soluble group-10 α-diimine catalyst precursors, catalysts and methods for dimerizing and oligomerizing olefins This invention relates to late transition metal catalyst precursors and catalysts for olefin dimerizations and oligomerizations, and to methods for making and using these catalysts. ... | 01/09/2007 |
| 7138376 | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides A compound, method and composition for treating a host infected with a hepatitis C viral comprising administering an effective hepatitis C treatment amount of a described 4′-disubstituted nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is prov... | 11/21/2006 |
| 7109343 | Metal catalysts and methods for making and using same Compounds having the formula: are disclosed. M1 and M2 are the same or different and are transition metal atoms or ions; Z2 and Z3, independently, are the atoms necessa... | 09/19/2006 |
| 7053020 | Catalyst systems for ethylene oligomerisation to linear alpha olefins A catalyst system comprising: (a) one or more bisarylimino pyridine iron or cobalt catalysts; (b) a first co-catalyst compound which is selected from aluminium alkyls, aluminoxanes, and mixtures thereof; and ... | 05/30/2006 |
| 7049442 | Ligands and catalyst systems thereof for ethylene oligomerisation to linear alpha olefins Mixed bis-imine pyridine ligands of formula (I), wherein Z1, which is different from Z2, is an optionally substituted aryl group; and Z2 comprises an optionally substituted heterohydrocarbyl moiety, or an optionally substituted aryl ... | 05/23/2006 |
| 6946532 | Catalysts containing per-ortho aryl substituted aryl or heteroaryl substituted nitrogen donors Catalyst compositions useful for the polymerization of olefins are disclosed. These compositions comprise a Group 8-10 metal complex comprising a bidentate or variable denticity ligand comprising one or two nitrogen donor atom or atoms independently substituted by a... | 09/20/2005 |
| 6930136 | Adhesion promoters containing benzotriazoles Benzotriazole adducts contain a benzotriazole segment and a segment with a curable and polymerizable functionality, or an adhesion promoting functionality, particularly suitable for use on metal substrates or in adhesive, sealant or coating compositions for use in p... | 08/16/2005 |
| 6919456 | Catalytic compositions and methods for asymmetric aldol reactions Methods and compositions are provided for the direct catalytic asymmetric aldol reaction of aldehydes with donor molecules selected from ketones and nitroalkyl compounds. The reactions employ as catalyst a Group 2A or Group 2B metal complex of a ligand of formula I,... | 07/19/2005 |
| 6844446 | Catalysts containing per-ortho aryl substituted aryl or heteroaryl substituted nitrogen donors Catalyst compositions useful for the polymerization of olefins are disclosed. These compositions comprise a Group 8-10 metal complex comprising a bidentate or variable denticity ligand comprising one or two nitrogen donor atom or atoms independently substituted by a... | 01/18/2005 |
| 6838478 | Amino acid derivatives and their use as thrombin inhibitors There is provided compounds of formula I, wherein R1, R2, R3, Rx, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like... | 01/04/2005 |
| 6825356 | Catalysts containing N-pyrrolyl substituted nitrogen donors Catalyst compositions useful for the polymerization or oligomerization of olefins are disclosed. Certain of the catalyst compositions comprise N-pyrrolyl substituted nitrogen donors. Also disclosed are processes for the polymerization or oligomerization of olefins u... | 11/30/2004 |
| 6762304 | Metal catalysts and methods for making and using same Compounds having the formula: are disclosed. M1 and M2 are the same or different and are transition metal atoms or ions; Z2 and Z3, independently, are the atoms necessary to co... | 07/13/2004 |
| 6706891 | Process for the preparation of ligands for olefin polymerization catalysts Processes for the preparation of 4,5-bisimino-[1,3]dithiolanes and 2,3-bisimino-[1,4]dithianes are described. The processes involve conversion of an oxalamide to a dithiooxalamide, followed by conversion of the dithiooxalamide to either a 4,5-bisimino-[1,3]dithiolan... | 03/16/2004 |
| 6599894 | Amidinobenzylamine derivatives and their use as thrombin inhibitors There is provided compounds of formula I ##STR1## wherein R1, R2, Y, R3 and R4 have meanings given in the description which are useful as, or as prodrugs of, competitive inhibitors of trypsin-like proteases, suc... | 07/29/2003 |
| 6552051 | Energetic nitramine-linked azoles and related compounds as oxidizers, initiators and gas generators Novel compounds are provided having the structural formula R[--N(NO2)--L--R1 ]n wherein R, L, R1 and n are defined herein. The compounds are useful in a variety of contexts, but are primarily to be used as high ... | 04/22/2003 |
| 6544992 | Urotensin-II receptor antagonists The present invention relates to pyrrolyl and pyridyl derivatives, pharmaceutical compositions containing them and their use as inhibitors of urotensin II.... | 04/08/2003 |
| 6512001 | D-proline derivatives New compounds have the formula: ##STR1## wherein R, R1, X and Y have the meanings described herein. Methods are set forth for synthesizing these compounds and using these compounds to treat diseases associated with amyloidosis, such as Alzheime... | 01/28/2003 |
| 6492402 | Thrombin inhibitors The present invention relates to a compound having formula I: ##STR1## and pharmaceutically acceptable salts thereof. The compounds of formula I and pharmaceutical compositions containing them are of the class of thrombin inhibitors which are useful as an... | 12/10/2002 |
| 6462048 | Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors The present invention relates to lactam derivatives of the formula ##STR1## wherein R1, R2, R3, A, X, Z, n and the dashed line are defined herein, and pharmaceutical compositions thereof, to processes and intermediates for... | 10/08/2002 |
| 6420380 | Hepatitis C inhibitor tri-peptides Racemates, diastereoisomers and optical isomers of a compound of formula (I): ##STR1## wherein B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C1-6 alk... | 07/16/2002 |
| 6413987 | Dermal anesthetic agents The present invention relates to new aminoindane piperidine compounds, the method of using aminoindane compounds as local anesthetics, said compounds having particularly valuable properties as dermal and topical anesthetics in mammals, including man, as w... | 07/02/2002 |
| 6350774 | Antithrombotic agents This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and ... | 02/26/2002 |
| 6329417 | Hepatitis C inhibitor tri-pepitides Racemates, diastereolsomers and optical isomers of a compound of formula (I): ##STR1## wherein B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C1-6 ... | 12/11/2001 |
| 6323180 | Hepatitis C inhibitor tri-peptides A racemate, diastereoisomer and optical isomer of a compound of formula (I): ##STR1## wherein B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which may be optionally substituted with C1-... | 11/27/2001 |
| 6316475 | Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications Compounds of formula (I) ##STR1## are useful in treating diseases or conditions prevented by or ameliorated with histamine-3 receptor ligands.... | 11/13/2001 |
| 6316505 | Pharmaceutical compositions comprising fluorinated co-polymers Block copolymers containing a fluorinated hydrocarbon unit, a hydrocarbon unit, and a poly(oxyethylene) unit are useful in fluid formulations of pharmaceutical agents. A typical embodiment is: C11 H23 --CONHC2 H4 NHC... | 11/13/2001 |
| 6310061 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists A compound of the following formula: ##STR1## and the salts thereof, wherein A is hydrogen, halo, or hydroxy; the broken line represents an optional double bond with proviso that if the broken line is a double bond, then A is absent; Ar1 is opt... | 10/30/2001 |
| 6310080 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors Selected amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, rela... | 10/30/2001 |
| 6303602 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists A compound of the following formula: ##STR1## or a salt thereof, wherein A is hydrogen, halo, hydroxy; the broken line represents an optional double bond with proviso that if the broken line is a double bond, then A is absent; Ar1 is optionally... | 10/16/2001 |
| 6294569 | Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists A compound of the following formula: ##STR1## and the salts thereof, wherein A is hydrogen, halo, hydroxy, or the like; the broken line represents an optional double bond with proviso that if the broken line is a double bond, then A is absent; Ar1 | 09/25/2001 |
| 6284756 | Antithrombotic agents This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the ... | 09/04/2001 |
| 6271227 | Antithrombotic Agents This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and ... | 08/07/2001 |
